Novel therapies are changing treatment paradigms in metastatic prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Hematol Oncol
Main Authors: Powers, Eric, Karachaliou, Georgia Sofia, Kao, Chester, Harrison, Michael R., Hoimes, Christopher J., George, Daniel J., Armstrong, Andrew J., Zhang, Tian
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594418/
https://ncbi.nlm.nih.gov/pubmed/33115529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00978-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares